BiotechTube

sutimlimab (BIVV009) + placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cold Agglutinin Disease

Conditions

Cold Agglutinin Disease

Trial Timeline

Mar 17, 2018 → Dec 3, 2021

NCT ID
NCT03347422

About sutimlimab (BIVV009) + placebo

sutimlimab (BIVV009) + placebo is a phase 3 stage product being developed by Sanofi for Cold Agglutinin Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03347422. Target conditions include Cold Agglutinin Disease.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03347422Phase 3Completed

Competing Products

20 competing products in Cold Agglutinin Disease

See all competitors
ProductCompanyStageHype Score
THB001Third Harmonic BioPhase 1
25
Nasal Glucagon + OxymetazolineEli LillyPhase 1
33
New Formulation Phenylephrine HCl + Marketed Phenylephrine HCl + PlaceboJohnson & JohnsonPhase 2
52
Pseudoephedrine/ParacetamolJohnson & JohnsonApproved
85
DFV890NovartisPhase 2
52
Lidocaine 8mg + CPC 2mg + Lidocaine 1mg + CPC 2mgNovartisPhase 3
77
Omalizumab + Omalizumab + PlaceboNovartisPhase 2
52
Dextromethorphan + PlaceboNovartisApproved
85
XylometazolineNovartisPhase 3
77
Penciclovir + PlaceboNovartisApproved
85
N-acetylcysteine + PlaceboNovartisPhase 2
52
Advil Congestion Relief + Advil Allergy and Congestion Relief + ParacetamolPfizerPhase 3
76
pseudoephedrine hydrochloride 30 mg tablets + Placebo tabletsPfizerPhase 3
76
Pegcetacoplan + Placebo matching PegcetacoplanSwedish Orphan BiovitrumPhase 3
76
sutimlimabSanofiPhase 3
76
Dupilumab SAR231893 + Placebo + Non sedating H1-antihistamineSanofiPhase 3
76
BIVV009SanofiPhase 3
76
rilonacept 160 mg + Placebo + rilonacept 160 mgRegeneron PharmaceuticalsPhase 3
76
Rilonacept + PlaceboRegeneron PharmaceuticalsPhase 2
51
HSK39004 Dry Powder Inhaler -0.75mg BID + HSK39004 Dry Powder Inhaler -1.5mg BID + HSK39004 Inhalation Suspension -3mg BID + HSK39004 PlaceboHaisco Pharmaceutical GroupPhase 2
49

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84